ECHOGO® AMYLOIDOSIS
Cardiac Amyloidosis Screening
Advanced AI for screening patients with cardiac amyloidosis
- check FDA-cleared
- check Live in top U.S. hospitals
- check Seamless integration with echo workflows
Cardiac amyloidosis is severly undiagnosed
Cardiac amyloidosis remains undiagnosed and many patients experience delays before receiving a diagnosis.¹⁻⁴ Studies have shown the disease is substantially more prevalent among patients with HFpEF.⁵
Cardiac amyloidosis patients may remain undiagnosed¹⁻⁴
Estimated cardiac amyloidosis prevalence within HFpEF⁵
Median hospital visits before ATTR diagnosis⁶
Cardiac amyloidosis flagged from a single echo scan.
EchoGo® Amyloidosis analyzes a single apical four chamber view to screen for cardiac amyloidosis, helping clinicians identify patients who may benefit from further evaluation directly from routine echocardiography.
Clinically evaluated⁷, FDA-cleared, and granted FDA Breakthrough Device Designation.
Cardiac amyloidosis screening and HFpEF identification in one workflow
The same study is also analyzed by EchoGo® Heart Failure to support HFpEF identification, helping identify patients with overlapping disease risk, with no additional scanning steps required.
Built around the way echo teams already work
EchoGo® Amyloidosis findings are returned directly into existing clinical systems, allowing clinicians to review AI results alongside routine echocardiography studies with no additional workflow steps require.
See how clinicians are using EchoGo® Amyloidosis
Learn how healthcare organizations are incorporating advanced AI for cardiac amyloidosis screening into routine echocardiography workflows.
Dr. Andres Schuster at University Hospitals
"We used EchoGo® Amyloidosis in both cases. Both were flagged as suggestive of cardiac amyloidosis and were subsequently confirmed positive with biopsy."
Dr. Faizi Jamal at City of Hope
"That clarity has made our reports far more actionable. Referring physicians now have something concrete to act on. We are providing information that prompts people to intervene."
CLINICALLY EVALUATED
Trained, validated and tested across 12.5k+ real-world cases.
EchoGo® Amyloidosis was validated across 18+ global sites in a large-scale international study published in the European Heart Journal. Developed by Ultromics with Mayo Clinic, it was tested with investigators at The University of Chicago Medicine and collaborators worldwide.
Performance has been evaluated in both peer-reviewed studies and real-world clinical settings.⁷
PEER-REVIEWED
European Heart Journal
Clinical sites
Chicago Medicine + 18 global sites.
Independent multisite validation.
real-world cases
12,500+
In clinical evaluation under intended-use conditions, EchoGo® Amyloidosis demonstrated 84.5% sensitivity and 89.7% specificity. See FDA 510(k) K240860 for full results.
Featured in respected journals.
Automatically screens for cardiac amyloidosis from a single apical four chamber view.
Studies are also analyzed for hidden HFpEF.
Helps identify patients who may benefit from further evaluation.
Findings flagged directly within
your echo workflow.
Automated from analysis to billing.
End-to-end automated workflow, from study analysis and report delivery through to automated billing.
Built to scale across echo labs and health systems.
Cloud-based infrastructure designed to scale across echo labs, hospitals, and health systems, from one site to enterprise-wide adoption.
Designed for secure healthcare deployment.
HIPAA compliant, Cyber Essentials certified, ISO 27001 certified, and ISO 13485 certified.
Integrated into the workflow you already run.
Connects with ultrasound systems and PACS through secure cloud infrastructure, with no disruption to how your team works.
CUSTOMER ONBOARDING
Deploy with confidence. Simple onboarding. Designed to fit your workflow.
-
Step 01 - Discovery
Understand requirements, infrastructure, and workflow.
-
Step 02 - Connect
Configure secure routing and validate DICOM flow.
-
Step 03 - Go live
Begin receiving AI findings from Ultromics directly into your existing clinical systems.
-
Step 04 - Scale
Expand across workstations and teams.
-
What is EchoGo® Amyloidosis?
EchoGo® Amyloidosis is an FDA-cleared AI screening tool designed to identify patients who may have cardiac amyloidosis and could benefit from further diagnostic testing
-
Who is EchoGo® Amyloidosis intended for?
EchoGo® Amyloidosis is indicated for adults aged 65 years and older with heart failure undergoing echocardiographic assessment
-
How accurate is EchoGo® Amyloidosis?
Clinical validation demonstrated 85% sensitivity, 93% specificity, and an AUROC of 0.93 across more than 12,500 cases.
-
How does EchoGo® Amyloidosis fit into existing workflows?
Echo studies are automatically analyzed and results are returned directly into existing clinical systems with no additional scanning steps required.
-
How quickly are results available?
EchoGo® Amyloidosis typically returns findings in less than 20 minutes, supporting review during routine echo interpretation
EchoGo® Amyloidosis 1.0 is FDA 510(k)-cleared. Rx only, for use by or on the order of a physician. Available in the United States only.
¹ González-López E et al. European Heart Journal. 2015;36:2585-2594.
² AbouEzzeddine OF et al. JAMA Cardiology. 2021;6:1267-1274.
³ Borlaug BA et al. Journal of the American College of Cardiology. 2023;81:1810-1834.
⁴ Hahn VS et al. JACC: Heart Failure. 2020;8:712-724.
⁵ Grogan M et al. Heart. 2017;103:1065-1072.
⁶ Slivnick JA, Hawkes W et al. European Heart Journal. 2025. doi:10.1093/eurheartj/ehaf387.
Ready to see EchoGo® Amyloidosis in practice?
Speak with a local rep in your area to learn more.